OCULAR THERAPEUTIX, INC Cash Flow Statement
OCUL / Health Care|14 years of annual SEC 10-K data (FY2012-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 14 fiscal years. All figures from audited SEC 10-K filings.
OCULAR THERAPEUTIX, INC used $205M in operating cash flow and negative free cash flow of $217M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 0.25 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$265.9M | -$193.5M | -$80.7M | -$155.6M | -$86.4M | -$86.4M | -$63.4M | -$60.0M | -$63.4M | -$44.7M | -$13.3M | -$14.1M | -$13.3M | -$14.1M |
| Depreciation & Amortization | $4.3M | $3.8M | $3.0M | $2.8M | $2.5M | $2.5M | $1.6M | $2.3M | $1.6M | $881.0K | $404.0K | $404.0K | $404.0K | $404.0K |
| Operating Cash Flow | -$204.9M | -$134.7M | -$70.2M | -$53.6M | -$77.6M | -$77.6M | -$50.5M | -$49.2M | -$50.5M | -$34.0M | -$12.6M | -$12.6M | -$12.6M | -$12.6M |
| Capital Expenditures | $12.0M | $1.3M | $6.1M | $841.0K | $2.2M | $2.2M | $8.3M | $1.9M | $8.3M | $1.9M | $387.0K | $203.0K | $387.0K | $203.0K |
| Free Cash Flow | -$216.9M | -$136.0M | -$76.3M | -$54.4M | -$79.8M | -$79.8M | -$58.7M | -$51.1M | -$58.7M | -$35.9M | -$13.0M | -$12.8M | -$13.0M | -$12.8M |
| FCF Margin | -417.5% | -213.4% | -130.6% | -312.6% | -1888.2% | -1888.2% | -3053.8% | -2568.6% | -3053.8% | -1903.5% | -1688.1% | -127880.0% | - | - |